LIOS and Estonian company TBD Pharmatech partner to develop active compound for smoking cessation

NMR instument

On September 1st, 2023, TBD Pharmatech together with the Latvian Institute of Organic Synthesis started a new project PharmaBoost – EstLat Alliance in Drug Development. The total project funding is 582.436,25 EUR, with a substantial 80% contribution coming from the Estonia–Latvia Programme 2021–2027.

This partnership embarks on a journey dedicated to advancing pharmaceutical development within the Baltic States. The primary goal is to pioneer an economically and environmentally sustainable production technology of an active pharmaceutical ingredient (API) crucial for a vital smoking cessation medication.

Furthermore, the project is promoting pharmaceutical innovation in the Baltic region. Estonia and Latvia share common challenges within their pharmaceutical sectors, characterized by a limited number of industry players, substantial entry barriers, a scarcity of skilled workforce, and infrastructure gaps. Through this collaboration, the Estonian partner, a GMP-certified producer of APIs, and the Latvian partner, with over 60 years of drug design and technology expertise, aspire to surmount these obstacles.

Collectively, the partnership aims to establish a more resilient pharmaceutical landscape, reinforced by a proficient workforce, cutting-edge infrastructure, and cross-border cooperation.

The project is scheduled from September 1st, 2023, to April 30th, 2025.

For an overview of the Interreg VI-A Estonia-Latvia Programme 2021–2027, please see here.


logo: project name "Interreg" and EU flag